AACR logo

More articles from Therapeutic Agents: Biological

Abstract C028: Discovery and characterization of next generation monoclonal antibodies targeting the inhibitory Fc gamma receptor CD32b for the treatment of B and plasma cell malignancies
Haihui Lu, Dongshu Chen, Sunyoung Jang, Babette Wolf, Stefan Ewert, Meghan Flaherty, Fangmin Xu, Sinan Isim, Yeonjiu Shim, Christina Dornelas, Nicole Balke, Xavier Charles Leber, Meike Scharenberg, Johanna Koelln, Eugene Choi, Rebecca Ward, Jennifer Johnson, Thomas Calzascia, Isabelle Isnardi, Juliet Williams, Heather Huet, Emma Lees, Matthew J Meyer

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C028; DOI: 10.1158/1535-7163.TARG-19-C028
Abstract C031: Ras processing by RRSP protease as a strategy to inhibit Ras-driven tumors
Vania Vidimar, Greg L Beilhartz, Roman A Melnyk, Karla JF Satchell

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C031; DOI: 10.1158/1535-7163.TARG-19-C031
Abstract C026: DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
Daisuke Okajima, Junko Yamaguchi, Michiko Kitamura, Reiko Kamei, Takanori Maejima, Tomoko Shibutani, Satoru Yasuda, Tadashi Toki, Tsuyoshi Karibe, Tomomichi Fujitani, Takashi Nakada, Riki Goto, Yutaka Noguchi, Yuki Abe, Toshinori Agatsuma

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C026; DOI: 10.1158/1535-7163.TARG-19-C026
Abstract C032: A novel integrin-targeted therapeutic agent for ovarian cancer
Franics S Markland, Steve Swenson, Radu Minea, Louis Dubeau

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C032; DOI: 10.1158/1535-7163.TARG-19-C032
Abstract C027: A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort
Johanna Bendell, Susanna V Ulahannan, Quincy Chu, Manish Patel, Ben George, Renee Landsberg, Mabrouk Elgadi, Christine Duffy, Ralph Graeser, Wenbo Tang, Michael Merger, Miaomiao Ge, Melissa Johnson

Molecular Cancer Therapeutics Dec 2019, 18 (12 Supplement) C027; DOI: 10.1158/1535-7163.TARG-19-C027
Abstract B121: The benefits of bispecific mAb² antibodies targeting EGFR and HGF
Kin-Mei Leung

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B121; DOI: 10.1158/1535-7163.TARG-17-B121
Abstract B107: Antitumor activity of new antibody-drug conjugate with eribulin in triple-negative breast cancer PDX
Marc Hillairet de Boisferon, Caroline Mignard, Coralie Durix, Toshimitsu Uenaka, Katherine Rybinski, Xin Cheng, Keiji Furuuchi, Eart Albone

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B107; DOI: 10.1158/1535-7163.TARG-17-B107
Abstract B103: A multi-analyte HPLC-MS/MS approach to assessing exposure of a Probody drug conjugate in preclinical studies
Laura Serwer, Shweta Singh, Claus Krebber, Shouchun Liu, Niharika Chauhan, Robert Leanna, Hong Lu, Ilaria Badagnani, Tracy Henriques, Susan Morgan-Lappe, William Mylott, Sridhar Viswanathan, Jennifer Richardson, Michael Kavanaugh

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B103; DOI: 10.1158/1535-7163.TARG-17-B103
Abstract B109: ASN004, a novel 5T4-targeted Dolaflexin ADC, causes complete and durable tumor regression in a variety of tumor xenograft models
Roger A. Smith, David J. Zammit, Sanjeeva P. Reddy

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B109; DOI: 10.1158/1535-7163.TARG-17-B109
Abstract B114: Humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibit tumor growth in vitro and in vivo
Daniel Dransfield, Jillian M. Prendergast, David A. Eavarone, Rawan Nazer, Linah Al-Alem, Bo Rueda, Jenna Stein, Jeff Behrens

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B114; DOI: 10.1158/1535-7163.TARG-17-B114

Main menu

User menu

Search

More articles from Therapeutic Agents: Biological

Pages

Articles

Info for

About MCT